With more than two decades of experience as a physician, pharmaceutical industry veteran and sell side analyst, Dr. Jim Birchenough has covered a broad range of small-, mid- and large-cap biotech companies. He has an emphasis on clinical discovery and emerging technologies and companies and is highly rated in various investor surveys. He holds a Post-Graduate Medical Residency and a Medical Doctorate from McMaster University and a Bachelor of Science in physiology from McGill University.
"We are maintaining our Outperform rating on SNSS; we see significant upside potential on novel BTK inhibitor SNS062."
Jim Birchenough, Wells Fargo & Co.